

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Lockyer CONF. NO.: 1674
SERIAL NO.: 10/560,956 GROUP NO.: Not yet assigned
FILING DATE: December 15, 2005 EXAMINER: Not yet assigned
TITLE: METHODS FOR IDENTIFYING COMPOUNDS INTERACTING
WITH SMALL MEMBRANE-BOUND GTP-ASES

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or

(2) after the period defined in (1) but before the mailing date of a **final action or a notice of allowance** under 37 C.F.R. 1.311, and

Information Disclosure Statement

U.S. Serial No.: 10/560,956

Atty. Docket No.: MKC-008

- the requisite Statement is below, **OR**
- the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**
- the requisite Statement is below, **AND**
- the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.


STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Information Disclosure Statement
U.S. Serial No.: 10/560,956
Atty. Docket No.: MKC-008

Respectfully submitted,


Randall D. Morin
Randall D. Morin
Attorney for Applicants
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Goodwin Customer No. 051414

Date: July 19, 2006
Reg. No. 58,312

Tel. No.: (617) 570-1657
Fax No.: (617) 523-1231

VER 9/00
LIBC/2798334.1

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: MKC-008 APPLICANT(S): Lockyer SERIAL NO.: 10/560,956 FILING DATE: December 15, 2005			
---	--	--	--	---	--	--	--

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENG LANG (Y/N)
	B1	WO 98/37196	08/27/1998	PCT					Y
	B2	WO 02/008245	01/31/2002	PCT					Y
	B3	WO 02/052272	07/04/2002	PCT					Y

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C1	Barbacid, M., "ras GENES" (1987) <u>Ann. Rev. Biochem.</u> 56: 779-827.
	C2	Bos, J., "ras Oncogenes in Human Cancer: A Review" (1989) <u>Cancer Research</u> 49(17): 4682-4689.
	C3	Campbell, S., <i>et al.</i> , "Increasing complexity of Ras signaling" (1988) <u>Oncogene</u> 17(11): 1395-1413.
	C4	Chiu, V. <i>et al.</i> , "Ras signalling on the endoplasmic reticulum and the Golgi" (2002) <u>Nature Cell Biology</u> 4: 343-350.
	C5	Cichowski, K. <i>et al.</i> , "NF1 Tumor Suppressor Gene Function: Narrowing the GAP" (2001) <u>Cell</u> 104(4): 593-604.
	C6	Cullen, P. <i>et al.</i> , "Integration of Calcium and Ras Signaling" (2002) <u>Nature Reviews Molecular Cell Biology</u> 3(5): 339-348.
	C7	Dorn, G. <i>et al.</i> , "Intracellular Transport Mechanisms of Signal Transducers" (2002) <u>Annu. Rev. Physiol.</u> 64:407-29.
	C8	Dorn, G. <i>et al.</i> , "Sustained <i>in vivo</i> cardiac protection by a rationally designed peptide that causes ε protein kinase C translocation" (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96(22): 12798-12803.
EXAMINER		DATE CONSIDERED

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO.: MKC-008 APPLICANT(S): Lockyer SERIAL NO.: 10/560,956 FILING DATE: December 15, 2005
---	---

OTHER ART, JOURNAL ARTICLES, ETC.

EXAMINER INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
C9	Gibbs, J. <i>et al.</i> , "Modulation of Guanine Nucleotides Bound to Ras in NIH3T3 Cells by Oncogenes, Growth Factors, and the GTPase Activating Protein (GAP)" (1990) <i>Jrl. of Biol. Chem.</i> 265(33): 20437-20442.
C10	Hoa, M. <i>et al.</i> , "Amplification of Wild-Type K-ras Promotes Growth of Head and Neck Squamous Cell Carcinoma" (2002) <i>Cancer Research</i> 62(24): 7154-7156.
C11	Kato-Stankiewicz, J. <i>et al.</i> , "Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells" (2002) <i>Proc. Natl. Acad. Sci. USA</i> 99:14398-14403.
C12	Kim, S.H. <i>et al.</i> , "E-cadherin -mediated Cell-Cell Attachment Activates Cdc42" (2000) <i>Jrl. of Biol. Chem.</i> 275: 36999-37005.
C13	Lockyer, P. <i>et al.</i> , "CAPRI regulates Ca ²⁺ -dependent inactivation of the Ras-MAPK pathway" (2001) <i>Current Biology</i> 11(12): 981-986.
C14	Nori M. <i>et al.</i> , "Inhibition of v-src-Induced Transformation by a GTPase-Activating Protein" (1991) <i>Molecular and Cellular Biology</i> 11(5): 2812-2818.
C15	Rodriquez, M. <i>et al.</i> , "RACK1, a Protein Kinase C Anchoring Protein, Coordinates the Binding of Activated Protein Kinase C and Select Pleckstrin Homology Domains in Vitro" (1999) <i>Biochemistry</i> 38(42): 13787-13794.
C16	Ron, D. <i>et al.</i> , "An autoregulatory region in protein kinase C: The pseudoanchoring site" (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92(2): 492-496.
C17	Ron, D. <i>et al.</i> , "Cloning of an intracellular receptor for protein kinase C: A homolog of the β subunit of G proteins" (1994) <i>Proc. Natl. Acad. Sci. USA</i> 91(3): 839-843.
C18	Ron, D. <i>et al.</i> , "C2 Region-derived Peptides Inhibit Translocation and Function of β Protein Kinase C <i>in Vivo</i> " (1995) <i>Jrl. of Biol. Chem.</i> 270(41): 24180-24187.
C19	Smith, M. <i>et al.</i> , "Requirement for c-ras proteins during viral oncogene transformation" (1986) <i>Nature</i> 320(6062): 540-543.
C20	Srinivasan, S., "Rac and Cdc42 play distinct roles in regulating PI(3,4,5)P ₃ and polarity during neutrophil chemotaxis" (2003) <i>Jrl. of Cell Biology</i> 160: 375-385.
C21	International Search Report for International Application No. PCT/GB2004/001765, completed September 10, 2004, 1 page.
C22	Great Britain Search Report under Section 17 for Application No.: GB 0314980.4, completed October 13, 2003, 1 page.
EXAMINER	DATE CONSIDERED